Plain-English translation of NCT06839547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is tracking how a new anti-cancer medication works when given together with radiation therapy to treat breast cancer that has spread to the brain. Researchers want to understand whether this medication helps make the radiation more effective and whether it is safe for patients. The study will follow about 100 patients across multiple hospitals.
When breast cancer spreads to the brain, it becomes very difficult to treat. Doctors believe that giving this new medication at the same time as radiation might help the radiation work better and improve outcomes for patients, but this approach needs to be carefully studied.
You likely qualify if…
You likely don't qualify if…
This is an observational study, which means researchers will track your medical care rather than assign you to a specific treatment. You would continue receiving your regular cancer treatment — the radiation therapy and anti-cancer medication that your doctor has already recommended — while the research team monitors your progress and collects information about how you respond. Your medical records will be reviewed throughout your treatment to evaluate how well the medication and radiation work together and whether you experience any side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Enrollment target
~100 participants
Started
March 2025
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fei Ma, Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.